Drug intelligence / Profile preview

MLAB004

Development stage: Preclinical
Lead developer: MLAB Biosciences
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

MLAB004 is an investigational therapeutic candidate currently in the discovery and preclinical stages of development for the treatment of osteoarthritis (OA). Developed by MLAB Biosciences, a biotechnology company focused on musculoskeletal and neuromuscular diseases, the program is part of a pipeline that includes several assets for muscular dystrophies. As of 2024, specific details regarding the drug's modality, molecular target, and mechanism of action have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on MLAB004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MLAB004.

Explore the full profile